Search Results | Blood | American Society of Hematology

1-20 of 527

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

DOI: https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

DOI: https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

Constipated plasma cells in extranodal marginal zone lymphoma of the lung

Jinjun Cheng, Elaine S. Jaffe

Blood (2019) 134 (24): 2226.

DOI: https://doi.org/10.1182/blood.2019003455

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

DOI: https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

DOI: https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

DOI: https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

DOI: https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

DOI: https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

DOI: https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

DOI: https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

Shi Hui Clarice Choong, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD, Sanjay De Mel, BSc, BM, Te-Chih Liu, FRCPath, MBBS, MRCP, Bei Jenny Li, Li Mei Michelle Poon, Shir Ying Lee, FRCPath,MBBS,MRCP,, Hoon Chung Tae, Rebecca Teng, Seok Wei Stephrene Chan

Blood (2019) 134 (Supplement_1): 5253.

DOI: https://doi.org/10.1182/blood-2019-125241

Published: 2019

Journal Articles

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Edward Briercheck, MD, Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Oscar Silva, MD PhD, Maneka Puligandla, MS, Marcos Mauricio Siliézar Tala, MD, Timothy Guyon, MSc, Samuel L. Dixon, BS, Robert Terbrueggen, PhD, Yasodha Natkunam, MD PhD, Kristen E. Stevenson, MS, David M Weinstock

Blood (2019) 134 (Supplement_1): 409.

DOI: https://doi.org/10.1182/blood-2019-121397

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

DOI: https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data

Wolfgang Kern, MD, Franz Elsner, PhD, Max Zhao, Nanditha Mallesh, Richard Schabath, PhD, Claudia Haferlach, MD, Peter Krawitz, MD, Hannes Lueling, PhD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 886.

DOI: https://doi.org/10.1182/blood-2019-130374

Published: 2019

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

DOI: https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease

Surbhi Sidana, MD, David L Murray, MD PhD, Surendra Dasari, PhD, Ronald S. Go, MD, Maria Alice Willrich, PhD, Melissa Snyder, PhD, Mindy Kohlhagen, John A. Lust, MD PhD, Eli Muchtar, MD, Taxiarchis Kourelis, MD, Shaji K. Kumar, MD, Angela Dispenzieri, MD, Morie A. Gertz, MD

Blood (2019) 134 (Supplement_1): 3510.

DOI: https://doi.org/10.1182/blood-2019-121712

Published: 2019

Journal Articles

Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18

Agnieszka Malecka, Jan Delabie, MD PhD, Ingunn Ostlie, Anne Tierens, MD PhD, Ulla Randen, MD PhD, Sigbjorn Berentsen, MD PhD, Geir Erland Tjønnfjord, MD PhD, Gunhild Trøen

Blood (2019) 134 (Supplement_1): 1488.

DOI: https://doi.org/10.1182/blood-2019-121750

Published: 2019

Journal Articles

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Blood (2019) 134 (Supplement_1): 1610.

DOI: https://doi.org/10.1182/blood-2019-126068

Published: 2019

Journal Articles

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma

Sanjal Desai, MD, Stephen Fernandez, Anusha Vakiti, MD, Facundo Stingo, MD, Tripti Adhikari, MD, Emily Paku, Aarthi Shenoy, MD, Vera Malkovska, MD, Dawn Fishbein, MD

Blood (2019) 134 (Supplement_1): 1614.

DOI: https://doi.org/10.1182/blood-2019-127520

Published: 2019

Journal Articles

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Akihiko Sawaki, MD, Kana Miyazaki, MD PhD, Toshifumi Takeuchi, MD PhD, Kyoko Kobayashi, MD PhD, Hiroshi Imai, MD PhD, Isao Tawara, MD PhD, Ryoichi Ono, MD PhD, Tetsuya Nosaka, MD PhD, Motoko Yamaguchi, MD PhD, Naoyuki Katayama, MD PhD

Blood (2019) 134 (Supplement_1): 1624.

DOI: https://doi.org/10.1182/blood-2019-122796

Published: 2019

2 3 4 5

NARROW

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Constipated plasma cells in extranodal marginal zone lymphoma of the lung

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease

Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only